Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 5, 2003, Pages 1689-1693

  Critchley, Ian A ^a   Blosser Middleton, Renée S ^a   Jones, Mark E ^b   Thornsberry, Clyde ^c   Sahm, Daniel F ^a   Karlowsky, James A ^a  

^a Focus Technologies Incorporated   (United States)

^b Focus Technologies   (Netherlands)

^c Focus Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; DEMOGRAPHY; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; UNITED STATES;

EID: 0037659210     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.5.1689-1693.2003     Document Type: Article

References (29)

1. Akins, R. L., and M. J. Rybak. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide-intermediate Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459.
2. Alborn, W. E., Jr., N. E. Allen, and D. A. Preston. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. 35:2282-2287.
3. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1919-1922.
4. Bhavnani, S. M., and C. H. Ballow. 2000. New agents for gram-positive bacteria. Curr. Opin. Microbiol. 3:528-534.
5. Bodi, M., C. Ardanuy, and J. Rello. 2001. Impact of gram-positive resistance on outcome of nosocomial pneumonia. Crit. Care Med. 29:82-86.
6. Dutka-Malen, S., S. Evers, and P. Courvalin. 1995. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 33:24-27.
7. Ehlert, F., and H. C. Neu. 1987. In vitro activity of LY146032 (daptomycin), a new peptolide. Eur. J. Clin. Microbiol. 6:84-90.
8. Eliopoulos, G. M., S. Willey, E. Reiszner, P. G. Spitzer, G. Caputo, and R. C. Moellering, Jr. 1986. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 30:532-535.
9. Fass, R. J., and V. L. Helsel. 1986. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrob. Agents Chemother. 30:781-784.
10. Flint, A. C., F. J. Schmitz, and J. Verhoef. 2001. Multiresistance to antimicrobial agents for the ten most frequently isolated bacterial pathogens. Int. J. Antimicrob. Agents 18:147-160.
11. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2000. Daptomycin susceptibility tests: interpretative criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. 38:51-58.
12. 2+ and albumin on these drugs. Antimicrob. Agents Chemother. 35:1710-1716.
13. Hodinka, R. L., L. Jack-Wait, N. Wannamaker, T. P. Walden, and P. H. Gilligan. 1987. Comparative in vitro activity of LY 146032 (daptomycin), a new lipopeptide antimicrobial. Eur. J. Clin. Microbiol. 6:100-103.
14. Jones, R. N. 1989. Effects of reduced cation supplement recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activity. J. Antimicrob. Chemother. 33:1652-1653.
15. Jones, R. N., and A. L. Barry. 1987. Antimicrobial activity and spectrum of activity of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob. Agents Chemother. 31:625-629.
16. Karchmer, A. W. 2000. Nosocomial bloodstream infections: organisms, risk factors and implications. Clin. Infect. Dis. 31:S139-S143.
17. King, A., and I. Phillips. 2001. The in vitro activity of daptomycin against 514 gram-positive aerobic clinical isolates. J. Antimicrob. Chemother. 48:219-223.
18. McGowan, J. E. 2001. Increasing threat of gram-positive bacterial infections in the intensive care unit setting. Crit. Care Med. 29:N67-N69.
19. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing; 12th informational supplement. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. Plouffe, J. F. 2000. Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid. Clin. Infect. Dis. 31:S144-S149.
21. Rybak, M. J., E. Hershberger, T. Moldovan, and R. G. Cruz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44:1062-1066.
22. Sahm, D. F., J. A. Karlowsky, L. J. Kelly, I. A. Critchley, M. E. Jones, C. Thornsberry, Y. Mauriz, and J. Kahn. 2001. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 45:1037-1042.
23. Schentag, J. J. 2001. Antimicrobial management strategies for gram-positive bacterial resistance in the intensive care unit. Crit. Care Med. 29:N100-N107.
24. Silverman, J. A., N. Oliver, T. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802.
25. Snydman, D. R., N. V. Jacobus, L. A. McDermott, J. R. Lonks, and J. M. Boyce. 2000. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob. Agents Chemother. 44:3447-3450.
26. Tally, F. P., M. Zeckel, M. M. Wasilewski, C. Carini, C. L. Berman, G. L. Drusano, and F. B. Oleson. 1999. Daptomycin: a novel agent for gram-positive infections. Expert Opin. Investig. Drugs 8:1223-1238.
27. Tally, F. P., and M. F. DeBruin. 2000. Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. 46:523-526.
28. Verbist, L. 1987. In vitro activity of LY 146032, a new lipopeptide antibiotic, against gram-positive cocci. Antimicrob. Agents Chemother. 31:340-342.
29. Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, C. Lexau, A. Reingold, L. Lefkowitz, P. R. Cieslak, M. Cetron, E. R. Zell, J. H. Jorgensen, and A. Schuchat. 2000. Increasing prevalence of multidrug resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343:1917-1924.